| Entry |
| ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Name | Quizartinib dihydrochloride (USAN); Quizartinib hydrochloride (JAN); Vanflyta (TN) | ||||||||
| Formula | C29H32N6O4S. 2HCl | ||||||||
| Exact mass | 632.1739 | ||||||||
| Mol weight | 633.5891 | ||||||||
| Structure |  | ||||||||
| Simcomp | |||||||||
| Class | Antineoplastic DG01918 Tyrosine kinase inhibitor DG01917 Receptor tyrosine kinase inhibitor Metabolizing enzyme substrate DG01633 CYP3A/CYP3A4 substrate | ||||||||
| Remark |
| ||||||||
| Efficacy | Antineoplastic, Receptor tyrosine kinase inhibitor | ||||||||
| Target | FLT3* (CD135) [HSA_VAR:2322v2] [HSA:2322] [KO:K05092] | ||||||||
| Pathway |
| ||||||||
| Metabolism | Enzyme: CYP3A [HSA:1576 1577 1551] | ||||||||
| Interaction | |||||||||
| Structure map |
| ||||||||
| Brite | Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS L01 ANTINEOPLASTIC AGENTS L01E PROTEIN KINASE INHIBITORS L01EX Other protein kinase inhibitors L01EX11 Quizartinib D09956 Quizartinib dihydrochloride (USAN) <JP> Therapeutic category of drugs in Japan [BR:br08301] 4 Agents affecting cellular function 42 Antineoplastics 429 Miscellaneous 4291 Other Antitumors D09956 Quizartinib dihydrochloride (USAN); Quizartinib hydrochloride (JAN) Drug groups [BR:br08330] Antineoplastic DG01918 Tyrosine kinase inhibitor DG01917 Receptor tyrosine kinase inhibitor DG01364 Quizartinib D09956 Quizartinib dihydrochloride Metabolizing enzyme substrate DG01633 CYP3A/CYP3A4 substrate DG01364 Quizartinib D09956 Quizartinib dihydrochloride Target-based classification of drugs [BR:br08310] Protein kinases Receptor tyrosine kinases (RTK) PDGFR family FLT3* (CD135) [HSA_VAR:2322v2] D09956 Quizartinib dihydrochloride (USAN) <JP> New drug approvals in Japan [br08318.html] Drugs with new active ingredients D09956 New drug approvals in the USA, Europe and Japan [br08328.html] Approval dates by FDA, EMA and PMDA D09956 Drug metabolizing enzymes and transporters [br08309.html] Drug metabolizing enzymes D09956 Pharmacogenomic biomarkers [br08341.html] Somatic variations in targeted cancer therapies D09956 Drug groups [BR:br08330] Antineoplastic DG01918 Tyrosine kinase inhibitor DG01917 Receptor tyrosine kinase inhibitor DG01364 Quizartinib Metabolizing enzyme substrate DG01633 CYP3A/CYP3A4 substrate DG01364 Quizartinib | ||||||||
| Other DBs |
| ||||||||
| KCF data | ATOM 42 1 C1x C 36.8200 -17.7100 2 O2x O 36.8200 -19.1100 3 C1x C 35.6300 -19.8100 4 C1x C 34.3700 -19.1100 5 N1y N 34.3700 -17.7100 6 C1x C 35.6300 -17.0100 7 C1b C 33.1800 -17.0100 8 C1b C 31.9900 -17.7100 9 O2a O 30.8000 -17.0100 10 C8y C 29.6100 -17.7100 11 C8x C 29.6100 -19.1100 12 C8x C 28.3500 -19.8100 13 C8y C 27.1600 -19.1100 14 C8y C 27.1600 -17.7100 15 C8x C 28.3500 -17.0100 16 N4y N 25.8300 -19.5300 17 C8y C 24.9900 -18.4100 18 S2x S 25.8300 -17.2900 19 C8x C 24.9900 -20.6500 20 C8y C 23.6600 -20.2300 21 N5x N 23.6600 -18.8300 22 C8y C 22.4700 -20.9300 23 C8x C 22.4700 -22.3300 24 C8x C 21.2800 -23.0300 25 C8y C 20.0200 -22.3300 26 C8x C 20.0200 -20.9300 27 C8x C 21.2800 -20.2300 28 N1b N 18.8300 -23.0300 29 C5a C 17.6400 -22.3300 30 N1b N 16.4500 -23.0300 31 O5a O 17.6400 -20.9300 32 C8y C 15.2600 -22.3300 33 N5x N 13.8600 -22.3300 34 O2x O 13.3700 -21.0000 35 C8y C 14.5600 -20.1600 36 C8x C 15.6800 -21.0000 37 C1d C 14.5600 -18.7600 38 C1a C 14.5600 -17.3600 39 C1a C 15.9600 -18.7600 40 C1a C 13.1600 -18.7600 41 X Cl 31.2200 -22.1900 42 X Cl 31.2200 -23.8000 BOND 45 1 1 2 1 2 2 3 1 3 3 4 1 4 4 5 1 5 5 6 1 6 1 6 1 7 5 7 1 8 7 8 1 9 8 9 1 10 9 10 1 11 10 11 1 12 11 12 2 13 12 13 1 14 13 14 2 15 14 15 1 16 10 15 2 17 13 16 1 18 16 17 1 19 17 18 1 20 14 18 1 21 16 19 1 22 19 20 2 23 20 21 1 24 17 21 2 25 20 22 1 26 22 23 1 27 23 24 2 28 24 25 1 29 25 26 2 30 26 27 1 31 22 27 2 32 25 28 1 33 28 29 1 34 29 30 1 35 29 31 2 36 30 32 1 37 32 33 2 38 33 34 1 39 34 35 1 40 35 36 2 41 32 36 1 42 35 37 1 43 37 38 1 44 37 39 1 45 37 40 1 |